.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Healthtrust
Federal Trade Commission
Fish and Richardson
Queensland Health
Dow
Argus Health
Chinese Patent Office
AstraZeneca
Cerilliant

Generated: July 21, 2017

DrugPatentWatch Database Preview

FOSAMPRENAVIR CALCIUM Drug Profile

« Back to Dashboard

Which patents cover Fosamprenavir Calcium, and what generic Fosamprenavir Calcium alternatives are available?

Fosamprenavir Calcium is a drug marketed by Mylan Pharms Inc and is included in one NDA.

The generic ingredient in FOSAMPRENAVIR CALCIUM is fosamprenavir calcium. There are four drug master file entries for this compound. Four suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the fosamprenavir calcium profile page.

Summary for Tradename: FOSAMPRENAVIR CALCIUM

Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list28
Clinical Trials: see list1,797
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FOSAMPRENAVIR CALCIUM at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc
FOSAMPRENAVIR CALCIUM
fosamprenavir calcium
TABLET;ORAL204060-001Apr 15, 2016ABRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Moodys
Teva
McKesson
McKinsey
US Department of Justice
Fuji
Farmers Insurance
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot